MoonLake Immunotherapeutics
MLTX
MLTX
111 hedge funds and large institutions have $2.67B invested in MoonLake Immunotherapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 39 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
2.56% less ownership
Funds ownership: 99.29% → 96.73% (-2.6%)
11% less capital invested
Capital invested by funds: $2.99B → $2.67B (-$315M)
24% less call options, than puts
Call options by funds: $5.49M | Put options by funds: $7.23M
Holders
111
Holding in Top 10
5
Calls
$5.49M
Puts
$7.23M
Top Buyers
| 1 | +$48.1M | |
| 2 | +$33M | |
| 3 | +$25.8M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.7M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$15.6M |
Top Sellers
| 1 | -$55M | |
| 2 | -$32M | |
| 3 | -$20.2M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$17M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$7.91M |